Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction

Am J Cardiol. 1990 Dec 1;66(19):1281-6. doi: 10.1016/0002-9149(90)91154-x.

Abstract

This study assesses whether administration of recombinant tissue-type plasminogen activator (rt-PA) up to 8 hours after onset of symptoms of acute myocardial infarction (AMI) may result in a significant improvement in left ventricular function. Sixty patients were classified into 3 groups: group A (n = 21) received rt-PA within 4 hours from symptom onset; the remaining 39 patients, admitted between 4 and 8 hours, were randomized into 2 groups--group B (n = 19) received rt-PA, and group C (n = 21) was treated with conventional therapy. Coronary and left ventricular angiograms were recorded 8 to 10 days after rt-PA administration. The patency rate of the infarct-related artery was 76% in group A, and 63 and 35% in group B and C, respectively. The Thrombolysis in Myocardial Infarction trial perfusion grade was higher in group A and B than in group C (A vs C: p less than 0.005; B vs C: p less than 0.01). Left ventricular ejection fraction was significantly higher in group A (60.2 +/- 10%) and B (54.7 +/- 12%) compared with group C (44.2 +/- 12%) (A vs C: p less than 0.01; B vs C: p less than 0.05). Regional wall motion of the entire ischemic zone was better in group A and B than in group C (A vs C: p less than 0.001; B vs C: p less than 0.01). In contrast, the kinesis of the central ischemic zone was significantly better in group A than in both group B and C (A vs B: p less than 0.05; A vs C: p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Coronary Angiography
  • Hemodynamics / drug effects
  • Humans
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / physiopathology
  • Recombinant Proteins / therapeutic use
  • Stroke Volume / drug effects
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use*
  • Vascular Patency / drug effects
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / physiology*

Substances

  • Recombinant Proteins
  • Tissue Plasminogen Activator